Diabetic Foot Infection (DFI) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Diabetic Foot Infection Emerging Therapy and TPP Insights

Thelansis’s “Diabetic Foot Infection (DFI) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Diabetic Foot Infection Overview

Diabetic foot infection (DFI) is an infection of skin and deeper tissues in a person with diabetes, often arising in an ulcer associated with neuropathy, pressure injury, or poor blood flow. Infection can spread to tendons, joints, or bone, causing osteomyelitis, tissue loss, sepsis, or amputation risk. Diagnosis is clinical and severity-based; properly collected tissue or bone samples can guide antibiotic choice. Treatment uses systemic antibiotics tailored to infection severity and culture results, with prompt drainage or debridement when abscess, necrosis, or severe infection is present. Good care also requires off-loading, wound management, circulation assessment, and glycemic control; revascularization may be needed when peripheral artery disease limits perfusion. Resistance, poor blood supply, and recurrent ulcers complicate healing. Phage therapy, biofilm-disrupting agents, and regenerative products remain investigational and are not substitutes for standard infection care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)